Nanogen Announces Appointment of Chief Financial Officer And A New Member To Its Board of Directors

Apr 30, 2001, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, April 30 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) announced
 today that Gerard Wills joined the Company as its Vice President, Chief
 Financial Officer and Treasurer, and that Randy White has been appointed to
 its Board of Directors.
     Gerard Wills, 48, will assume the position of Chief Financial Officer of
 the Company, a position held until now by Kieran Gallahue, who will
 concentrate his efforts solely on his duties as President of the Company.  Mr.
 Wills was the Chief Financial Officer, Vice President, Finance with Trega
 Biosciences, Inc. from 1999 prior to its acquisition by Lion Bioscience of
 Heidelberg, Germany in March 2001.  From 1993 to 1999, Mr. Wills was the Chief
 Financial Officer, Vice President, Finance with Molecular Biosystems, Inc. and
 from 1990 to 1993 he was Corporate Manager of Finance with Maxwell
 Laboratories, Inc.  Prior to 1990, Mr. Wills held a number of corporate
 controller and accounting positions with Intermark, Inc., Allied Signal and
 Ernst & Ernst.  Mr. Wills received his BBS in Accountancy from Notre Dame.
     Randy White, Ph.D, 53, who joins Nanogen's Board of Directors, has been
 the Executive Vice President Technical Operations and Research and Development
 for American Medical Laboratories, Inc. since 1998.  From 1992 to 1998, he was
 a consultant to a diverse group of diagnostic clinics including Unilab,
 Specialty Laboratories and California Community Clinics providing services
 relating to operational efficiency, systems and cost improvement.  From 1985
 to 1992, he was Executive Vice President, Operations for National Health
 Laboratories, Inc. ("NHL") and for the prior ten years he served in various
 upper managerial and operations roles with NHL.  Mr. White received a B.S. and
 a Ph.D. in Chemistry from the University of Houston.
     "We are very pleased to welcome Gerry and Randy to the Nanogen team,"
 stated Howard C. Birndorf, Chairman of the Board and Chief Executive Officer
 of Nanogen.  "Gerry brings over 25 years of experience in financial and
 accounting matters and specific expertise as a Chief Financial Officer at two
 public biotech companies where he was instrumental in developing and operating
 the financial, accounting and investor relations departments and in developing
 and maintaining relationships with institutional investors.  Randy contributes
 28 years of experience in the management and operations of clinical diagnostic
 labs, an important target market for Nanogen.  Over the last four months,
 Randy has been instrumental in establishing a collaboration between Nanogen
 and AML that may lead to the development of molecular diagnostic assays to be
 performed on the NanoChip(TM) Molecular Biology Workstation."
     Mr. Birndorf continued, "Gerry and Randy are valuable additions to the
 Company.  For the past year and a half, Nanogen has added key personnel to the
 management team and the board of directors to reflect the challenges and
 opportunities of our next phase of growth.  During this period we have also
 added Val Buonaiuto, Steve Papadopoulos and Dr. Regina Herzlinger to our
 Board.  Val and Steve bring their extensive experience in building commercial
 organizations and introducing new technologies to market and Regina
 contributes her broad accounting control and healthcare management expertise.
 We will continue this process of adding experience and depth to our board and
 management as we seek to establish the NanoChip(TM) System as the industry
 standard for performing genetic analyses in our targeted markets and to
 develop other products based on our platform technology."
     In other news, Nanogen also announced the resignation of Thomas G. Lynch,
 Executive Vice President and Chief Financial Officer of Elan Corporation, plc.
 from its Board of Directors.  With the acquisition of Dura Pharmaceuticals,
 Inc. by Elan Corporation, Mr. Lynch believes that Cam L. Garner, a consultant
 for Elan and former Chairman and Chief Executive Officer of Dura
 Pharmaceuticals who currently sits on the Nanogen Board, will effectively
 represent the continuing interests of Elan in the Company.
     Mr. Birndorf commented, "Tom came on our Board in February 1997 and helped
 us take the Company through its initial public offering in 1998 and then
 assisted us in transitioning from a research and development company to one
 that is products driven.  During Tom's four years on the Board, and his
 knowledge, expertise and assistance to the Company on important financial,
 accounting and compensation issues were invaluable.  We wish Tom well in his
 future endeavors and we look forward to continuing our association with Elan
 through Cam's representation."
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen System is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) System can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000, filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X66491449
 
 

SOURCE Nanogen, Inc.
    SAN DIEGO, April 30 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) announced
 today that Gerard Wills joined the Company as its Vice President, Chief
 Financial Officer and Treasurer, and that Randy White has been appointed to
 its Board of Directors.
     Gerard Wills, 48, will assume the position of Chief Financial Officer of
 the Company, a position held until now by Kieran Gallahue, who will
 concentrate his efforts solely on his duties as President of the Company.  Mr.
 Wills was the Chief Financial Officer, Vice President, Finance with Trega
 Biosciences, Inc. from 1999 prior to its acquisition by Lion Bioscience of
 Heidelberg, Germany in March 2001.  From 1993 to 1999, Mr. Wills was the Chief
 Financial Officer, Vice President, Finance with Molecular Biosystems, Inc. and
 from 1990 to 1993 he was Corporate Manager of Finance with Maxwell
 Laboratories, Inc.  Prior to 1990, Mr. Wills held a number of corporate
 controller and accounting positions with Intermark, Inc., Allied Signal and
 Ernst & Ernst.  Mr. Wills received his BBS in Accountancy from Notre Dame.
     Randy White, Ph.D, 53, who joins Nanogen's Board of Directors, has been
 the Executive Vice President Technical Operations and Research and Development
 for American Medical Laboratories, Inc. since 1998.  From 1992 to 1998, he was
 a consultant to a diverse group of diagnostic clinics including Unilab,
 Specialty Laboratories and California Community Clinics providing services
 relating to operational efficiency, systems and cost improvement.  From 1985
 to 1992, he was Executive Vice President, Operations for National Health
 Laboratories, Inc. ("NHL") and for the prior ten years he served in various
 upper managerial and operations roles with NHL.  Mr. White received a B.S. and
 a Ph.D. in Chemistry from the University of Houston.
     "We are very pleased to welcome Gerry and Randy to the Nanogen team,"
 stated Howard C. Birndorf, Chairman of the Board and Chief Executive Officer
 of Nanogen.  "Gerry brings over 25 years of experience in financial and
 accounting matters and specific expertise as a Chief Financial Officer at two
 public biotech companies where he was instrumental in developing and operating
 the financial, accounting and investor relations departments and in developing
 and maintaining relationships with institutional investors.  Randy contributes
 28 years of experience in the management and operations of clinical diagnostic
 labs, an important target market for Nanogen.  Over the last four months,
 Randy has been instrumental in establishing a collaboration between Nanogen
 and AML that may lead to the development of molecular diagnostic assays to be
 performed on the NanoChip(TM) Molecular Biology Workstation."
     Mr. Birndorf continued, "Gerry and Randy are valuable additions to the
 Company.  For the past year and a half, Nanogen has added key personnel to the
 management team and the board of directors to reflect the challenges and
 opportunities of our next phase of growth.  During this period we have also
 added Val Buonaiuto, Steve Papadopoulos and Dr. Regina Herzlinger to our
 Board.  Val and Steve bring their extensive experience in building commercial
 organizations and introducing new technologies to market and Regina
 contributes her broad accounting control and healthcare management expertise.
 We will continue this process of adding experience and depth to our board and
 management as we seek to establish the NanoChip(TM) System as the industry
 standard for performing genetic analyses in our targeted markets and to
 develop other products based on our platform technology."
     In other news, Nanogen also announced the resignation of Thomas G. Lynch,
 Executive Vice President and Chief Financial Officer of Elan Corporation, plc.
 from its Board of Directors.  With the acquisition of Dura Pharmaceuticals,
 Inc. by Elan Corporation, Mr. Lynch believes that Cam L. Garner, a consultant
 for Elan and former Chairman and Chief Executive Officer of Dura
 Pharmaceuticals who currently sits on the Nanogen Board, will effectively
 represent the continuing interests of Elan in the Company.
     Mr. Birndorf commented, "Tom came on our Board in February 1997 and helped
 us take the Company through its initial public offering in 1998 and then
 assisted us in transitioning from a research and development company to one
 that is products driven.  During Tom's four years on the Board, and his
 knowledge, expertise and assistance to the Company on important financial,
 accounting and compensation issues were invaluable.  We wish Tom well in his
 future endeavors and we look forward to continuing our association with Elan
 through Cam's representation."
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen System is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) System can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000, filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X66491449
 
 SOURCE  Nanogen, Inc.